Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

$60m For Mexico’s Genomma From World Bank Group’s Private Sector Arm

The Investment Aims To Improve Medicines Access In Latin America And The Caribbean Region

Executive Summary

IFC, the private sector arm of the World Bank Group, has loaned $60m to Mexican Pharmaceutical Genomma, building on its long track record in Latin American health investments.

You may also be interested in...



Generics Bulletin’s Top 50 Ranking For 2022

This article compiles all the data from Generics Bulletin’s 2022 ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.

Genomma gets a cash injection

Mexican OTC medicines and personalcare specialist Genomma Lab has secured an investment package of almost US$100 million (€85 million) to help fund the ongoing construction of a production plant in its home country.

Hyloris Partner Signs To Market Maxigesic IV In Central And Eastern Europe

Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel